The Exchange has sought clarification from Sanofi India on March 29, 2017, with reference to the news flashed on www.reuters.com dated March 29, 2017 quoting ‘FDA Approves Regeneron, Sanofi $37,000 per year eczema drug’.
The above information is a part of company’s filings submitted to BSE.